REG - Uniphar PLC - Half Year Trading Update and Notice of Results

UnipharAnnouncement

29/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250729:nRSc8856Sa&default-theme=true

RNS Number : 8856S  Uniphar PLC  29 July 2025

 

 

Uniphar plc

 

Half-Year Trading Update and Notice of Results

 

Dublin, London | 29 July 2025: Uniphar plc (the "Group" or "Uniphar"), an
international diversified healthcare services business, today announces the
following unaudited trading update for the six months ended 30 June 2025.

 

The business achieved double-digit adjusted EPS growth in the first half of
2025, ahead of the Group's expectations, driven by a strong trading
performance with ca. 8% organic gross profit growth and lower finance costs.

 

Divisional performance:

 

·      Uniphar Pharma delivered double-digit organic gross profit growth
during the period and remains on track to deliver double-digit organic gross
profit growth for the full year.

 

·      Uniphar Medtech achieved high single-digit organic gross profit
growth during the half and expectations of high single-digit organic gross
profit growth for the full year remain unchanged.

 

·      Uniphar Supply Chain & Retail delivered low single-digit
organic gross profit growth during the half and remains on track to deliver
low single-digit organic gross profit growth for the full year.

 

The Group continues to maintain a strong liquidity position, with Net Bank
Debt/EBITDA of 1.9x at the end of June 2025. The €35m share buyback
programme announced with FY 2024 results was completed during the period.

 

Outlook

Uniphar enters the second half of this year with strong trading momentum.
Declining interest rates favourably impacting finance costs will be a tailwind
to current year EPS expectations.

 

M&A continues to play an important role in Uniphar's growth strategy, and
the Group maintains a disciplined approach to capital allocation, while
managing an active pipeline of acquisition opportunities to further enhance
the Group's growth potential.

 

Ger Rabbette, Uniphar Group Chief Executive Officer said:

 

"Uniphar has had a strong first half, achieving significant organic gross
profit growth. We expect to continue this progress into the second half and
meet our growth objectives for each of our three divisions for the full year.
 We remain confident of reaching our €200m EBITDA target by 2028, with at
least 80% of our growth being organic."

 

Notice of Results

 

The Group expects to publish its interim results for the six months ended 30
June 2025 at 07:00 am (BST) on 2 September 2025.

 

A conference call for analysts and investors will be held at 9.00 am (BST) on
2 September 2025 to discuss the Group's interim results. Analysts and
investors who wish to participate should visit www.uniphar.ie
(http://www.uniphar.ie)  to register.

 

The Company's interim results press release and presentation will also be
available on the website at 07.00 am (BST) on 2 September 2025
at www.uniphar.ie (http://www.uniphar.ie) .

 

 

--- ENDS ---

 

 

 

 

 

 

Contact details

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Daniel Saveski

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

 

About Uniphar plc

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply
Chain & Retail. The Group is active in Europe, North America, APAC and
MENA and delivers to 160+ countries.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

 

Uniphar Medtech

Uniphar Medtech is a leading Pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they can't source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTKZGZNRRDGKZM